These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 23463194)

  • 1. The burden and costs of prevention and management of genital disease caused by HPV in women: a population-based registry study in Finland.
    Salo H; Leino T; Kilpi T; Auranen K; Tiihonen P; Lehtinen M; Vänskä S; Linna M; Nieminen P
    Int J Cancer; 2013 Sep; 133(6):1459-69. PubMed ID: 23463194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
    Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
    PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
    J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.
    Insinga RP; Dasbach EJ; Elbasha EH
    Pharmacoeconomics; 2005; 23(11):1107-22. PubMed ID: 16277547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health and economic burden of HPV-related diseases in Singapore.
    Low JJ; Ko Y; Ilancheran A; Zhang XH; Singhal PK; Tay SK
    Asian Pac J Cancer Prev; 2012; 13(1):305-8. PubMed ID: 22502690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economic burden of human papillomavirus-related precancers and cancers in Sweden.
    Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C
    PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy.
    Giorgi Rossi P; Ricciardi A; Cohet C; Palazzo F; Furnari G; Valle S; Largeron N; Federici A
    BMC Public Health; 2009 Feb; 9():71. PubMed ID: 19243586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cervical cancer screening and associated treatment costs in France].
    Bergeron C; Breugelmans JG; Bouée S; Lorans C; Bénard S; Rémy V
    Gynecol Obstet Fertil; 2006 Nov; 34(11):1036-42. PubMed ID: 17070085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
    Dasbach EJ; Nagy L; Brandtmüller A; Elbasha EH
    J Med Econ; 2010 Mar; 13(1):110-8. PubMed ID: 20085477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
    Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Dillner J; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Maansson R; Lu S; Vuocolo S; Hesley TM; Saah A; Barr E; Haupt RM
    Cancer Prev Res (Phila); 2009 Oct; 2(10):868-78. PubMed ID: 19789295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology and costs of screening and management of precancerous lesions of the cervix in Spain.
    Castellsagué X; Rémy V; Puig-Tintoré LM; de la Cuesta RS; Gonzalez-Rojas N; Cohet C
    J Low Genit Tract Dis; 2009 Jan; 13(1):38-45. PubMed ID: 19098605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium.
    Annemans L; Rémy V; Lamure E; Spaepen E; Lamotte M; Muchada JP; Largeron N
    J Med Econ; 2008; 11(1):135-50. PubMed ID: 19450115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical management of abnormal cytology test results and costs associated with the prevention of cervical cancer in Spain.
    Blade A; Cararach M; Castro M; Catalá-López F; Pérez-Escolano I; de Sanjosé S
    J Low Genit Tract Dis; 2010 Oct; 14(4):311-8. PubMed ID: 20885158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.
    Brown RE; Breugelmans JG; Theodoratou D; Bénard S
    Curr Med Res Opin; 2006 Apr; 22(4):663-70. PubMed ID: 16684427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the epidemiology and morbidity burden associated with human papillomavirus in Israel: accounting for CIN1 and genital warts in addition to CIN2/3 and cervical cancer.
    Shavit O; Raz R; Stein M; Chodick G; Schejter E; Ben-David Y; Cohen R; Arbel D; Shalev V
    Appl Health Econ Health Policy; 2012 Mar; 10(2):87-97. PubMed ID: 22201263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The psychosocial burden of human papillomavirus related disease and screening interventions.
    Pirotta M; Ung L; Stein A; Conway EL; Mast TC; Fairley CK; Garland S
    Sex Transm Infect; 2009 Dec; 85(7):508-13. PubMed ID: 19703844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions.
    Sellors JW; Lorincz AT; Mahony JB; Mielzynska I; Lytwyn A; Roth P; Howard M; Chong S; Daya D; Chapman W; Chernesky M
    CMAJ; 2000 Sep; 163(5):513-8. PubMed ID: 11006761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries.
    Termrungruanglert W; Havanond P; Khemapech N; Lertmaharit S; Pongpanich S; Khorprasert C; Taneepanichskul S
    Value Health; 2012; 15(1 Suppl):S29-34. PubMed ID: 22265063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update of HPV-associated female genital cancers in the United States, 1999-2004.
    Watson M; Saraiya M; Wu X
    J Womens Health (Larchmt); 2009 Nov; 18(11):1731-8. PubMed ID: 19951205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.